Wedbush Has Optimistic Outlook of Biogen Q4 Earnings

Biogen Inc. (NASDAQ:BIIB) – Research analysts at Wedbush raised their Q4 2025 earnings per share (EPS) estimates for shares of Biogen in a note issued to investors on Friday, May 2nd. Wedbush analyst L. Chico now expects that the biotechnology company will earn $3.95 per share for the quarter, up from their previous forecast of $3.87. The consensus estimate for Biogen’s current full-year earnings is $15.83 per share. Wedbush also issued estimates for Biogen’s Q1 2026 earnings at $4.06 EPS, Q2 2026 earnings at $4.06 EPS, Q3 2026 earnings at $3.94 EPS, Q4 2026 earnings at $3.73 EPS, FY2027 earnings at $16.97 EPS, FY2028 earnings at $20.23 EPS and FY2029 earnings at $20.95 EPS.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings data on Thursday, May 1st. The biotechnology company reported $3.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.26 by ($0.24). The company had revenue of $2.43 billion during the quarter, compared to analyst estimates of $2.25 billion. Biogen had a return on equity of 14.98% and a net margin of 16.87%. The company’s revenue was up 6.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $3.67 EPS.

BIIB has been the topic of a number of other reports. William Blair reissued an “outperform” rating on shares of Biogen in a research report on Monday, January 13th. BMO Capital Markets reduced their target price on Biogen from $156.00 to $139.00 and set a “market perform” rating for the company in a research report on Thursday, February 13th. HSBC cut shares of Biogen from a “buy” rating to a “hold” rating and set a $118.00 price objective for the company. in a research note on Monday, April 28th. Needham & Company LLC reissued a “hold” rating on shares of Biogen in a research report on Friday. Finally, Morgan Stanley lowered their price objective on Biogen from $157.00 to $152.00 and set an “equal weight” rating on the stock in a research note on Wednesday, April 9th. Twenty research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $194.56.

Biogen Stock Performance

NASDAQ BIIB opened at $121.80 on Monday. The company’s fifty day moving average is $130.21 and its two-hundred day moving average is $145.97. Biogen has a 52-week low of $110.04 and a 52-week high of $238.00. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.35 and a quick ratio of 0.90. The firm has a market capitalization of $17.83 billion, a price-to-earnings ratio of 10.88, a P/E/G ratio of 1.51 and a beta of 0.13.

Institutional Trading of Biogen

A number of institutional investors have recently bought and sold shares of the business. Signaturefd LLC lifted its stake in shares of Biogen by 3.5% in the 4th quarter. Signaturefd LLC now owns 2,092 shares of the biotechnology company’s stock valued at $320,000 after purchasing an additional 71 shares during the period. Quent Capital LLC increased its holdings in Biogen by 31.9% in the fourth quarter. Quent Capital LLC now owns 298 shares of the biotechnology company’s stock valued at $46,000 after purchasing an additional 72 shares during the last quarter. Principal Securities Inc. lifted its stake in Biogen by 30.1% in the fourth quarter. Principal Securities Inc. now owns 337 shares of the biotechnology company’s stock valued at $52,000 after buying an additional 78 shares during the period. Wealth Enhancement Advisory Services LLC boosted its holdings in Biogen by 1.6% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 5,018 shares of the biotechnology company’s stock worth $767,000 after buying an additional 79 shares during the last quarter. Finally, Israel Discount Bank of New York grew its position in shares of Biogen by 6.2% during the 4th quarter. Israel Discount Bank of New York now owns 1,405 shares of the biotechnology company’s stock worth $215,000 after buying an additional 82 shares during the period. Institutional investors and hedge funds own 87.93% of the company’s stock.

Insider Buying and Selling at Biogen

In related news, Director Stephen A. Sherwin sold 8,760 shares of the business’s stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $150.02, for a total transaction of $1,314,175.20. Following the completion of the sale, the director now directly owns 11,318 shares of the company’s stock, valued at $1,697,926.36. The trade was a 43.63 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 0.16% of the company’s stock.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.